These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23400750)

  • 1. Feasibility of a breath test for monitoring adherence to vaginal administration of antiretroviral microbicide gels.
    Morey TE; Wasdo S; Wishin J; Quinn B; van der Straten A; Booth M; Gonzalez D; Derendorf H; Melker RJ; Dennis DM
    J Clin Pharmacol; 2013 Jan; 53(1):103-11. PubMed ID: 23400750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel breath test to directly measure use of vaginal gel and condoms.
    van der Straten A; Cheng H; Wasdo S; Montgomery L; Smith-McCune K; Booth M; Gonzalez D; Derendorf H; Morey TE; Dennis DM
    AIDS Behav; 2013 Jul; 17(6):2211-21. PubMed ID: 23321948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
    Abdool Karim Q; Abdool Karim SS; Frohlich JA; Grobler AC; Baxter C; Mansoor LE; Kharsany AB; Sibeko S; Mlisana KP; Omar Z; Gengiah TN; Maarschalk S; Arulappan N; Mlotshwa M; Morris L; Taylor D;
    Science; 2010 Sep; 329(5996):1168-74. PubMed ID: 20643915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaginal deployment and tenofovir delivery by microbicide gels.
    Gao Y; Yuan A; Chuchuen O; Ham A; Yang KH; Katz DF
    Drug Deliv Transl Res; 2015 Jun; 5(3):279-94. PubMed ID: 25874971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.
    Rosen RK; Morrow KM; Carballo-Diéguez A; Mantell JE; Hoffman S; Gai F; Maslankowski L; El-Sadr WM; Mayer KH
    J Womens Health (Larchmt); 2008 Apr; 17(3):383-92. PubMed ID: 18328009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covert use, vaginal lubrication, and sexual pleasure: a qualitative study of urban U.S. Women in a vaginal microbicide clinical trial.
    Hoffman S; Morrow KM; Mantell JE; Rosen RK; Carballo-Diéguez A; Gai F
    Arch Sex Behav; 2010 Jun; 39(3):748-60. PubMed ID: 19636696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
    Sokal DC; Karim QA; Sibeko S; Yende-Zuma N; Mansoor LE; Baxter C; Grobler A; Frolich J; Kharsany AB; Miya N; Mlisana K; Maarshalk S; Karim SS
    Antivir Ther; 2013; 18(3):301-10. PubMed ID: 22914267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maximized mucoadhesion and skin permeation of anti-AIDS-loaded niosomal gels.
    Zidan AS; Habib MJ
    J Pharm Sci; 2014 Mar; 103(3):952-64. PubMed ID: 24464823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, comparative safety study of a prefilled plastic and user-filled paper applicator with candidate microbicide tenofovir 1% gel.
    Cohen JA; Brache V; Foster J; Cochon L; Callahan M; Schwartz J
    Sex Transm Dis; 2013 Jun; 40(6):476-81. PubMed ID: 23677021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits.
    Clark MR; Friend DR
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1458-66. PubMed ID: 22394281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study.
    MacQueen KM; Weaver MA; van Loggerenberg F; Succop S; Majola N; Taylor D; Karim QA; Karim SA
    AIDS Behav; 2014 May; 18(5):826-32. PubMed ID: 24647763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reformulated tenofovir gel for use as a dual compartment microbicide.
    Dezzutti CS; Rohan LC; Wang L; Uranker K; Shetler C; Cost M; Lynam JD; Friend D
    J Antimicrob Chemother; 2012 Sep; 67(9):2139-42. PubMed ID: 22581908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial.
    Succop SM; MacQueen KM; van Loggerenberg F; Majola N; Karim QA; Karim SS
    AIDS Care; 2014; 26(12):1521-5. PubMed ID: 25285564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial.
    Mureithi MW; Poole D; Naranbhai V; Reddy S; Mkhwanazi NP; Sibeko S; Werner L; Abdool Karim Q; Abdool Karim S; Ndung'u T; Altfeld M;
    J Acquir Immune Defic Syndr; 2012 Jun; 60(2):124-7. PubMed ID: 22362152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.
    Shankar GN; Alt C
    J Antimicrob Chemother; 2014 Dec; 69(12):3282-93. PubMed ID: 25139839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a composite measure of product adherence, protocol compliance, and semen exposure using DNA and protein biomarkers for topical HIV prevention studies.
    Jacot TA; Nelson A; Thurman A; Kashuba AD; Archer DF; Doncel GF
    PLoS One; 2014; 9(12):e114368. PubMed ID: 25489736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel.
    Thurman AR; Chandra N; Yousefieh N; Kimble T; Anderson SM; Cottrell M; Sykes C; Kashuba A; Schwartz JL; Doncel GF
    J Acquir Immune Defic Syndr; 2018 May; 78(1):82-92. PubMed ID: 29424790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.
    Chopera DR; Mann JK; Mwimanzi P; Omarjee S; Kuang XT; Ndabambi N; Goodier S; Martin E; Naranbhai V; Karim SA; Karim QA; Brumme ZL; Ndung'u T; Williamson C; Brockman MA;
    PLoS One; 2013; 8(8):e71758. PubMed ID: 24015191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy.
    Beigi R; Noguchi L; Parsons T; Macio I; Kunjara Na Ayudhya RP; Chen J; Hendrix CW; Mâsse B; Valentine M; Piper J; Watts DH
    J Infect Dis; 2011 Nov; 204(10):1527-31. PubMed ID: 21930612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.
    Naranbhai V; Abdool Karim SS; Altfeld M; Samsunder N; Durgiah R; Sibeko S; Abdool Karim Q; Carr WH;
    J Infect Dis; 2012 Oct; 206(7):993-1001. PubMed ID: 22829639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.